



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ruben et al.

Docket No.: PF524P1

Application No.: 09/961,376

Confirmation No.: 6600

Filed: September 25, 2001

Art Unit: 1646

For: Human Tumor Necrosis Factor Receptor TR-17

Examiner: P. M. Mertz

**RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed May 14, 2004, please enter the following provisional election, with traverse, and consider the remarks below. Applicants submit concurrently herewith:

- (a) a Fee Transmittal, together with the appropriate fee(s);
- (b) Supplemental Information Disclosure Statement Pursuant to 37 C.F.R. § 1.56 and 1.97(c), (with a revised Form PTO/SB/08 and copies of references B1-B5);
- (c) Exhibit A: GenBank report for GenBank Accession Number NP\_036584;
- (d) Exhibit B: An alignment of the protein of SEQ ID NO:2 with TACI; and
- (e) a Petition for Extension of Time of two (2) months.

Prior to further examination, Applicants respectfully request entry of the following amendments.

Amendments to the Claims begin on page 2.

Remarks begin on page 5.